Standardizing patient-derived models to test microencapsulated nutraceuticals with immunotherapy in NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project standardizes a platform of patient-derived organotypic models, including tissue slices and tumoroids, to evaluate the efficacy of microencapsulated nutraceutical compounds alone and in combination with immunotherapies in NSCLC. It uses spatial transcriptomics to characterize responses in models derived from patients with resectable disease. The work is organized into three independent work packages led by IRCCS Istituto Nazionale Tumori Regina Elena and collaborators, focusing on model standardization, compound characterization, and translational traceability. The study collects specimens from untreated NSCLC patients undergoing curative surgery to inform future therapeutic strategies and product development. Interventions are non-pharmacological and experimental, centered on model-based testing rather than active patient treatment in this phase.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients over 18 years of age;
* Patients diagnosed with resectable NSCLC who will undergo curative surgery;
* Patients who give written informed consent (study participation and data processing).

Exclusion criteria:

* Previous malignancies;
* Previous systemic treatments.

Where it's running

• IRCCS National Cancer Institute "Regina Elena"
  Rome, Rome, Italy Recruiting

Study contacts

• Principal investigator: Paola Nisticò, Medical Doctor — IRCCS "Regina Elena" National Cancer Institude
• Study coordinator: Paola Nisticò, Medical Doctor
• Email: paola.nisticò@ifo.it
• Phone: +39 06 52662539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.